Champions Oncology Reports Revenue of $16.6 Million

NodeGuardian · 2026-03-30T02:02:04+00:00

Champions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, with year-over-year growth and positive adjusted EBITDA expected. Study service revenue rose 32%, despite a slight overall revenue decrease due to lack of a major data license transaction.

NodeGuardian

2026-03-30 02:02:04

Abstract generation in progress

Champions Oncology, Inc. announced its financial results for the third quarter of fiscal 2026, reporting revenue of $16.6 million. The company is on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year, despite a slight decrease in total revenue compared to the prior year period due to the absence of a large data license transaction. Study service revenue increased by 32% year-over-year, reflecting strong study execution and conversion of previously booked work.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.